Product Center
Abundant achievements, showcasing technological hard power
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-12-15
- Views:
(Summary description)Recently, a press conference on the evaluation results of unicorn enterprises and gazelle enterprises in Jiangsu's high-tech zone was held in Nanjing. Ab&B Bio Tech CO., LTD. JS was identified as a po
Abundant achievements, showcasing technological hard power
(Summary description)Recently, a press conference on the evaluation results of unicorn enterprises and gazelle enterprises in Jiangsu's high-tech zone was held in Nanjing. Ab&B Bio Tech CO., LTD. JS was identified as a po
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-12-15 16:19
- Views:
Recently, a press conference on the evaluation results of unicorn enterprises and gazelle enterprises in Jiangsu's high-tech zone was held in Nanjing. Ab&B Bio Tech CO., LTD. JS was identified as a potential unicorn enterprise in Jiangsu Province.
Potential unicorn enterprises in Jiangsu Province are innovative enterprises with strong innovation capabilities, fast growth rates, and great development potential. They are a barometer of urban innovation vitality and industrial ecology, with high growth potential, strong innovation, and enormous potential. They are an important force leading industrial transformation in the new economic track. The recognition of potential unicorn enterprises in Jiangsu Province this time is a high recognition of the company's innovation and development level, and also a strong witness to the strength of Zhonghui Biotechnology's hard technology. Recently, the company's technological innovation and development have added fruitful results. The company's independently developed freeze-dried human rabies vaccine (human diploid cells) has made new progress and obtained the implied clinical trial license from the National Medical Products Administration. This variety has also become the fifth product of the company to enter the clinical stage, further enriching the company's product lineup and demonstrating the company's technological strength.
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
